Related Experiment Video
Updated: Jul 18, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Amyotrophic lateral sclerosis in Nova Scotia.
Advances in Experimental Medicine and Biology
|January 1, 1987
Summary
This study tracked Amyotrophic Lateral Sclerosis (ALS) in Nova Scotia over ten years. Findings suggest an increasing incidence of ALS, with higher rates in the latter half of the study period.
Area of Science:
- Neurology
- Epidemiology
Background:
- Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease.
- Understanding ALS incidence is crucial for public health and research.
Purpose of the Study:
- To determine the incidence of ALS in Nova Scotia over a ten-year period.
- To investigate trends in ALS incidence within the study population.
Main Methods:
- A retrospective study was conducted over a ten-year period.
- Data was collected through cooperation with medical professionals and hospitals.
- Population data for Nova Scotia was utilized to calculate incidence rates.
Main Results:
- A total of 161 ALS cases were identified over ten years.
- The overall incidence rate was 1.95 per 100,000 population.
- Incidence increased from 1.50 per 100,000 in the first five years to 2.40 per 100,000 in the latter five years.
- Peak incidence occurred in 1981-1982 at 2.66 per 100,000.
Conclusions:
- The study suggests an increasing trend in ALS incidence in Nova Scotia.
- The observed incidence may represent a more realistic rate due to enhanced ascertainment.
- Findings align with increasing ALS incidence noted in other international studies.
Related Concept Videos
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...